annual cash & cash equivalents:
$966.43M+$153.74M(+18.92%)Summary
- As of today (August 4, 2025), ALNY annual cash & cash equivalents is $966.43 million, with the most recent change of +$153.74 million (+18.92%) on December 31, 2024.
- During the last 3 years, ALNY annual cash & cash equivalents has risen by +$146.45 million (+17.86%).
- ALNY annual cash & cash equivalents is now at all-time high.
Performance
ALNY Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$1.11B+$94.03M(+9.22%)Summary
- As of today (August 4, 2025), ALNY quarterly cash & cash equivalents is $1.11 billion, with the most recent change of +$94.03 million (+9.22%) on June 30, 2025.
- Over the past year, ALNY quarterly cash & cash equivalents has increased by +$145.19 million (+14.99%).
- ALNY quarterly cash & cash equivalents is now -1.99% below its all-time high of $1.14 billion, reached on June 30, 2019.
Performance
ALNY quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ALNY Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +18.9% | +15.0% |
| 3 y3 years | +17.9% | +93.5% |
| 5 y5 years | +76.6% | +91.7% |
ALNY Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +18.9% | at high | +93.5% |
| 5 y | 5-year | at high | +94.6% | at high | +193.4% |
| alltime | all time | at high | +6144.3% | -2.0% | >+9999.0% |
ALNY Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $1.11B(+9.2%) |
| Mar 2025 | - | $1.02B(+5.5%) |
| Dec 2024 | $966.43M(+18.9%) | $966.43M(-12.1%) |
| Sep 2024 | - | $1.10B(+13.6%) |
| Jun 2024 | - | $968.49M(+42.0%) |
| Mar 2024 | - | $681.88M(-16.1%) |
| Dec 2023 | $812.69M(-6.2%) | $812.69M(-21.3%) |
| Sep 2023 | - | $1.03B(+57.0%) |
| Jun 2023 | - | $657.80M(-2.1%) |
| Mar 2023 | - | $672.25M(-22.4%) |
| Dec 2022 | $866.39M(+5.7%) | $866.39M(-19.3%) |
| Sep 2022 | - | $1.07B(+86.5%) |
| Jun 2022 | - | $575.56M(+7.8%) |
| Mar 2022 | - | $534.08M(-34.9%) |
| Dec 2021 | $819.98M(+65.1%) | $819.98M(-25.0%) |
| Sep 2021 | - | $1.09B(+46.7%) |
| Jun 2021 | - | $745.77M(+96.5%) |
| Mar 2021 | - | $379.54M(-23.6%) |
| Dec 2020 | $496.58M(-9.2%) | $496.58M(-0.0%) |
| Sep 2020 | - | $496.70M(-14.5%) |
| Jun 2020 | - | $580.83M(+24.2%) |
| Mar 2020 | - | $467.78M(-14.5%) |
| Dec 2019 | $547.18M(+30.2%) | $547.18M(-40.7%) |
| Sep 2019 | - | $923.30M(-18.7%) |
| Jun 2019 | - | $1.14B(+56.7%) |
| Mar 2019 | - | $724.96M(+72.5%) |
| Dec 2018 | $420.15M(-34.9%) | $420.15M(+32.7%) |
| Sep 2018 | - | $316.61M(-12.4%) |
| Jun 2018 | - | $361.46M(-8.8%) |
| Mar 2018 | - | $396.15M(-38.6%) |
| Dec 2017 | $645.36M(+233.3%) | $645.36M(+219.4%) |
| Sep 2017 | - | $202.04M(-50.6%) |
| Jun 2017 | - | $408.67M(+138.9%) |
| Mar 2017 | - | $171.08M(-11.6%) |
| Dec 2016 | $193.62M(+7.0%) | $193.62M(+14.9%) |
| Sep 2016 | - | $168.48M(-37.8%) |
| Jun 2016 | - | $271.08M(+17.2%) |
| Mar 2016 | - | $231.28M(+27.9%) |
| Dec 2015 | $180.90M(+140.6%) | $180.90M(+21.2%) |
| Sep 2015 | - | $149.22M(-1.4%) |
| Jun 2015 | - | $151.26M(-50.7%) |
| Mar 2015 | - | $306.58M(+307.8%) |
| Dec 2014 | $75.18M | $75.18M(-9.1%) |
| Sep 2014 | - | $82.72M(+2.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2014 | - | $80.73M(-77.0%) |
| Mar 2014 | - | $350.59M(+559.4%) |
| Dec 2013 | $53.17M(+3.4%) | $53.17M(+349.1%) |
| Sep 2013 | - | $11.84M(-52.6%) |
| Jun 2013 | - | $24.98M(-74.5%) |
| Mar 2013 | - | $97.80M(+90.3%) |
| Dec 2012 | $51.41M(-26.8%) | $51.41M(-32.2%) |
| Sep 2012 | - | $75.84M(+57.1%) |
| Jun 2012 | - | $48.27M(-21.8%) |
| Mar 2012 | - | $61.74M(-12.1%) |
| Dec 2011 | $70.23M(-5.9%) | $70.23M(-5.5%) |
| Sep 2011 | - | $74.34M(+10.8%) |
| Jun 2011 | - | $67.11M(-25.9%) |
| Mar 2011 | - | $90.59M(+21.4%) |
| Dec 2010 | $74.60M(-45.7%) | $74.60M(+59.1%) |
| Sep 2010 | - | $46.88M(-29.2%) |
| Jun 2010 | - | $66.18M(-42.4%) |
| Mar 2010 | - | $114.95M(-16.4%) |
| Dec 2009 | $137.47M(-28.3%) | $137.47M(+40.1%) |
| Sep 2009 | - | $98.09M(-33.7%) |
| Jun 2009 | - | $147.87M(-34.9%) |
| Mar 2009 | - | $227.27M(+18.5%) |
| Dec 2008 | $191.79M(+82.4%) | $191.79M(-2.5%) |
| Sep 2008 | - | $196.74M(-20.5%) |
| Jun 2008 | - | $247.54M(+26.1%) |
| Mar 2008 | - | $196.28M(+86.7%) |
| Dec 2007 | $105.16M(-17.8%) | $105.16M(-47.6%) |
| Sep 2007 | - | $200.55M(+137.4%) |
| Jun 2007 | - | $84.46M(+26.7%) |
| Mar 2007 | - | $66.66M(-47.9%) |
| Dec 2006 | $127.95M(+712.1%) | $127.95M(+260.3%) |
| Sep 2006 | - | $35.52M(-0.4%) |
| Jun 2006 | - | $35.65M(-37.2%) |
| Mar 2006 | - | $56.80M(+260.5%) |
| Dec 2005 | $15.76M(-22.3%) | $15.76M(+119.5%) |
| Sep 2005 | - | $7.18M(-21.7%) |
| Jun 2005 | - | $9.16M(-25.0%) |
| Mar 2005 | - | $12.21M(-39.7%) |
| Dec 2004 | $20.27M(-12.6%) | $20.27M(+39.4%) |
| Sep 2004 | - | $14.54M(-54.4%) |
| Jun 2004 | - | $31.89M(+47.6%) |
| Mar 2004 | - | $21.61M(-6.8%) |
| Dec 2003 | $23.19M(+49.9%) | $23.19M |
| Dec 2002 | $15.48M | - |
FAQ
- What is Alnylam Pharmaceuticals, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Alnylam Pharmaceuticals, Inc.?
- What is Alnylam Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
- What is Alnylam Pharmaceuticals, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Alnylam Pharmaceuticals, Inc.?
- What is Alnylam Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
What is Alnylam Pharmaceuticals, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of ALNY is $966.43M
What is the all time high annual cash & cash equivalents for Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $966.43M
What is Alnylam Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, ALNY annual cash & cash equivalents has changed by +$153.74M (+18.92%)
What is Alnylam Pharmaceuticals, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of ALNY is $1.11B
What is the all time high quarterly cash & cash equivalents for Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $1.14B
What is Alnylam Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, ALNY quarterly cash & cash equivalents has changed by +$145.19M (+14.99%)